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Abstract: Cancer is one of the leading causes of death both in developing countries and across the globe. In Indonesia, cancer 
ranks as the fifth primary cause of death following heart disease, stroke, respiratory tract and diarrhea. Therefore, studies on 
thiourea derivative compounds as anticancer agents have been profoundly conducted but still require further continuous 
development. In the present study, we aimed to synthesize new anticancer compounds of N-(phenylcarbamothioyl)-benzamide 
derivatives, namely N-(phenylcarbamothioyl)-4-bromobenzamide and N-(phenylcarbamothioyl)-4-fluorobenzamide compounds 
and assess their activities against MCF-7 breast cancer cells. The initial step was to predict the drug-receptor activity through 
docking between the tested compounds using epidermal growth factor receptor (EGFR) (PDB code: 1M17). The compounds 
were futher synthesized from the reactions between benzoyl chloride derivatives and N-phenylthiourea. The structures of the new 
compounds were identified  using FTIR, 1H NMR, 13C NMR and mass spectra. The cytotoxic activities (IC50) to breast cancer 
cells of MCF-7 N-(phenylcarbamothioyl)-4-bromobenzamide compound and N-(phenylcarbamothioyl)-4-fluorobenzamide were 
0.27 mM and 0.31 mM, respectively. These two new compounds had better cytotoxic activities than those of the current 
hydroxyurea-based anticancer drugs (the reference compound) with an IC50 value of 9.76 mM. Furthermore, these two new 
compounds were not toxic to Vero normal cells. Therefore, they possessed tremendous potentials as the candidates for new drugs 
against breast cancer.GG
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1. Introduction
The International Agency for Research on Cancer 
(IARC) has found that there were 14 067 894 new 
cases of cancer and 8 201 575 cancer-related deaths 
worldwide in 2012. Both lung and breast cancer are 
the leading causes of death compared with other types 
of cancer, with breast cancer ranks the top, especially 
in women. Ironically, it has been proposed that the 
prevalence of breast cancer is increased, and it becomes 
one of serious problems in  healthcare systems globally[1].
Thiourea is an organic compound consisting of 
carbon, nitrogen, sulfur and hydrogen atoms. The 
compound shares similarities  to urea except for the 
oxygen atoms, which are then replaced by sulfur. 
Hydroxyurea, nitrosourea and 5-fluorouracil are urea 
compounds still used today as anticancer drugs[2–4]. 
However, it has been widely reported that patients, 
particularly those with essential thrombocythaemia, 
have some adverse drug reactions when treated using 
hydroxyurea[5,6]. This results in the diminishing numbers 
of the clinical use of hydroxyurea, although, as a 
matter of fact, it is still used as a DNA replication 
inhibitor in biochemical research and development of
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the anticancer drugs[7]. Findings of research data have 
suggested that the hydrophilic properties of hydroxyurea 
are associated with the less optimal activity of this 
compound due to its poor membrane penetration ability. 
Therefore, it can be suggested that development of new 
anticancer drugs of urea and thiourea derivatives which have 
hydrophobic properties will result in better membrane 
penetration ability[8–11]. Li[9] has synthesized urea and 
thiourea derivatives and proved that phenylthiourea 
derivatives, N-(5-chloro-2-hydroxybenzyl)-N-(4-
hydroxybenzyl)-N'-phenylthiourea, have cytotoxic activity 
on MCF-7 cells by inhibiting EGFR and HER-2. 
Nakisah[10] has also shown that the compounds of 
2-[3-(2-methyl benzoyl)-thioureido]-acetic acid and 
2-[3-(4-methyl benzoyl)-thioureido]-acetic acid have 
cytotoxic activity against MCF-7 cells as well. 
In this present study, we synthesized N-(phenyl-
carbamothioyl)-4-bromobenzamide/4-Br-BPCT and 
N-(phenylcarbamothioyl)4-fluorobenzamide/4-F-BPCT. 
The presence of the substituents of bromo and fluoro at 
the benzoyl ring could enhance the lipophilic and 
electronic properties of these two compounds compared 
with their lead compound (BPCT). As a result, the drug 
and receptor bonds were improved, thus leading to the 
increased activities among  these two compounds[12–14]. 
This study was different from the study of Li[9] in 
regards to the different modification substrates. Study 
by Li has modified the benzyl groups, while our 
present study modified the benzoyl groups. This study 
was initiated with activity predictions using molecular 
modeling in silico and docking test compound with EGF 
(epidermal growth factor) Receptor PDB code: 1M17 
of Protein Data Bank (PDB). Molecular modeling 
was analyzed using Molegro Virtual Docker (MVD) 
program 5.5[15]. The activity prediction was carried out 
using EGFR receptor (1M17) because its ligand is 
Erlotinib[9], an anticancer drug which inhibits the EGFR 
pathway[4,9,16]. The test compounds were synthesized from 
N-phenylthiourea with R-benzoyl chloride (R = 4-Br and 
4-F) using an acyl nucleophilic substitution reaction[17,18]. 
The structures of the synthesized compounds were 
then identified with IR spectrophotometers, 1H NMR 
Spectrometers, 13C NMR and mass spectrometers[19].
The cytotoxic activities of the two test compounds 
were observed through cytotoxic assay using MTT method 
(3-(4,5-dimetylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide) in vitro on breast cancer cells MCF-7 and 
Vero normal cells[20]. After the identification of 
cytotoxic activity test on MCF-7 cells, the IC50 was 
then compared with hydroxyurea. Ourstudy might 
provide candidates of anticancer drugs from new 
thiourea derivatives, which have potent cytotoxic 
activity in breast cancer MCF-7 cells.
2. Materials and methods
2.1. Materials and instruments
Materials for synthesis included phenylthiourea, 
4-bromobenzoyl chloride, 4-fluorobenzoyl chloride 
(Sigma Aldrich), tetrahydrofuran (THF), triethylamine 
(TEA), acetone, ethyl acetate, n-hexane, chloroform 
and ethanol. Materials for activity test included test 
compounds and HU, cell cultures of MCF-7 and Vero, 
culture medium DMEM and M199, buffer saline 
phosphate (PBS), FBS (fetal bovine serum), trypsin, 
penicillin-streptomycin, fungizon, DMSO, 0.5 mg/mL 
MTT (3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) and SDS 10% in HCl 0.01 N. Glass tools for 
synthesis were Corning hot plate P351, Fisher-John 
Electrothermal Mel-Temp, Jasco FT-IR 5300 
Spectrophotometer, 1H NMR Spectrometer and 13C NMR 
Agilent 500 MHz with DD2 console system at 500 MHz 
(1H) and 125 MHz (13C) and mass Spectrometer (Waters). 
Tools for cytotoxic test included 5% CO2 incubator, 
LAF, micropipet with blue and yellow tip, test tube,
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vortex, 96-well microplate, conical tube, inverted 
microscope, hemocytometer and ELISA-reader. Molecular 
modeling: ChemBioDraw Ultra 15.0, Molegro Virtual 
Docker (MVD) 5.5.
2.2. Methods
2.2.1. Molecular modeling
Activities of new compounds were predicted using 
molecular modeling in silico, and docking of two test 
compounds with EGFR (epidermal growth factor receptor) 
PDB code: 1M17 of Protein Data Bank (PDB) was 
carried out using computer program Molegro Virtual 
Docker (MVD) 5.5. The EGFR receptor (1M17) was 
chosen because its ligand is Erlotinib[9], an anticancer 
drug, which inhibits EGFR pathway[4]. Hydroxyurea 
was used as a reference compound.
2.2.2. Synthesis of 4-Br-BPCT and 4-F-BPCT 
compounds
N-Phenylthiourea was mixed with THF and TEA 
in a round flask, and a solution of R-benzoyl chloride 
(R = 4-Br; 4-F) in THF was added into the mixture 
over the ice bath through a dropping funnel using a 
magnetic stirrer. The mixture was refluxed and stirred 
on top of a water bath. The reaction was terminated 
when the stain in the TLC formed a single stain. After 
the termination, THF was evaporated in the rotary 
evaporator. Then recrystallization was carried out[21].
The structures of new compounds were identified using 
spectroscopy: infrared, 1H NMR, 13C NMR and HRMS[19].
2.2.3. Cytotoxicity test of MTT assay method
MCF-7 and M199 cells were seeded into 96-well 
plates and then incubated for 24 h in 5% CO2 
incubators. Furthermore, test solutions, positive and 
negative controls of various concentrations were added. 
Each concentration was replicated for three times. Wells 
containing no cells and only filled with medium were used 
as medium controls. At the end of incubation, each well 
was added with 100 μL of 0.5 mg/mL MTT, followed 
by incubation for 3 h, and then the MTT reaction was 
discontinued by adding 100 μL of 10% SDS  in 0.01 N 
HCI into each well. The microplate was wrapped 
in paper and incubated at 37 ºC for 24 h. The live 
cells converted MTT into a dark blue formazan. 
Elisa reader was utilized to identify the absorption at 
λ = 595 nm. The IC50 values of the two test compounds 
and the reference compound were obtained  by using 
probit analysis[20,21].  
3. Results and discussion 
Drug activity was predicted in silico, and the RS value 
was used as the indicator. According to the result of in silico 
test (Table 1), the values of RS BFTU, 4-Br-BPCT, 
4-F-BPCT, RS HU were –76.9757, –85.4741, –83.5488 
and –38.4495, respectively. The smaller RS value 
indicated the more stable bonds between drug-receptors, 
leading to better activities[22]. The RS values of the two 
test compounds were smaller than those of the lead 
compound and the reference compound. The smaller 
values suggested their better activities.
The numbers and types of amino acids involved are 
listed in Table 2 and Figure 2. Based on the bonding of 
drugs and amino acids, it was predicted that the greater 
number of hydrogen bonds and steric bonds (Van der 
Waals and Hydrophobic) resulted in the more stable 
bonding between drugs and receptors, which might further 
affect the greater biological activity. The 4-Br-BPCT 
compound produced the largest number of bonds with 
amino acids at the EGFR receptor. Therefore, it was 
predicted that its activity as cytotoxic agents would 
be better than 4-F-BPCT, BFTU and HU. The better 
activity of the 4-Br-BPCT could be attributed to the 
higher lipophilic value of 4-Br (0.86) compared with 
4-F (0.14). Therefore, the membrane penetration of 
4-Br-BPCT was better than 4-F- BPCT, and the activities 
of 4-Br-BPCT were also improved[13,14].
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Compounds BPCT 4-Br-BPCT 4-F-BPCT HU
RS (kkal/mol) –76.9757 –85.4741 –83.5488 –38.4495
Cl
O
N
H
H2N
S
Addition
R
O
Cl
NH
S N
H
Elimination
N
H
O
N
H
S
R R
+    HCl
R = 4-Br
R = 4-F
R = 4-Br
R = 4-F
+
.. ....
..

Figure 1. Ligand interaction with amino acids at the EGFR binding sites where hydrogen bonds are indicated by blue dashed-lines, while steric 
interruptions are indicated by red dashed-lines: (a) BPCT compound, (b) 4-Br-BPCT compound, (c) 4-F-BPCT compound and (d) HU reference 
compound.G
Table 1. Rerank score (RS) value.G
Compounds
Amino acids
Thr 766 Val 702 Lys 721 Leu 764
BPCT 3S – – –
4-Br-BPCT 3S 1S 3S 1S
4-F-BPCT 4S – 1S –
HU 1H – – –
Table 2. Chemical and amino acid bonds involved in the interaction of 4-Br-BPCT and 4-F-BPCT compounds with EGFR (1M17).G
Description: H: Hydrogen bond and S: Steric bond (Van der Waals and Hydrophobic). G
Figure 2.  Reaction mechanism underlying the synthesis of 4-Br-BPCT and 4-F-BPCT.G
(a) BPCT  (b) 4-Br-BPCT
(c) 4-F-BPCT (d) HU 
Copyright © 2018 Journal of Chinese Pharmaceutical Sciences, School of Pharmaceutical Sciences, Peking University        http://www.jcps.ac.cn
ww
w.jc
ps.a
c.c
700

The 4-Br-BPCT and 4-F-BPCT compounds were 
synthesized from R-benzoyl chloride (R = 4-Br and 4-F) 
with N-phenylthiourea in one stage. The two compounds 
were yellow light crystals luster and insoluble in water. 
The structure of the synthesized compounds was 
identified by IR, 1H NMR, 13C NMR, and HRMS 
spectroscopy as follows:
N-(Phenylcarbamothioyl)-4-bromobenzamide: It was 
obtained as a yellow crystal, yield 67%,  m.p. 132–133 ºC. 
1H NMR (DMSO-d6, 500 MHz) δ: 7.29 (dd, J1 7.5 Hz, 
J2 2.0 Hz, 1H, Ar-H), 7.43 (t, J 7.5 Hz, 2H, Ar-H), 7.67 
(dd, J1 7.5 Hz, J2 2.0 Hz 2H, Ar-H), 7.69 (d, J 8.5 Hz, 
2H, Ar-H), 7.77 (d, J 8.5 Hz, 2H, Ar-H), 9.10 (s, 1H, 
O=C-NH-C=S), 12.50 (s, 1H, S=C-NH-Ar). 13C NMR 
(DMSO-d6, 125 MHz) δ: 124.27 (1C, Ar), 127.16 (2C, 
Ar), 129.08 (1C, Ar), 129.11 (2C, Ar), 129.14 (2C, Ar), 
130.55 (2C, Ar), 132.68 (1C, Ar), 137.59 (1C, Ar), 
166.16 (1C, C=O), 178.26 (1C, C=S). IR (KBr), νmax 
(cm–1): 1667 (C=O amide), 1596 and 1479 (C=C 
Aromatic); 3328 and 1596 (NH strech sec. amides); 
1077 and 830 (C=S). HRMS (m/z): C14H10N2OSBr 
(M-H)– = 332.9687 and Calc. Mass = 332.9697.
N-(Phenylcarbamothioyl)-4-fluorobenzamide: It was 
obtained as a yellow crystal, yield 45%,  m.p. 123–124 ºC. 
1H NMR (DMSO-d6, 500 MHz) δ: 7.21 (dd, J1 8.5 Hz, 
J2 2.0 Hz, 1H, Ar-H), 7.29 (d, J 7.6 Hz, 2H, Ar-H), 7.42 
(t, J 8.5 Hz, 2H, Ar-H), 7.70 (dd, J1 8.5 Hz, J2 2.0 Hz, 
2H, Ar-H), 7.93 (d, J 7.6 Hz, 2H, Ar-H), 9.12 (s, 1H, 
O=C-NH-C=S), 12.54 (s, 1H, S=C-NH-Ar). 13C NMR 
(DMSO-d6, 125 MHz) δ: 116.62 (2C, Ar), 124.26 (2C, Ar), 
127.50 (1C, Ar), 129.04 (1C, Ar), 130.29 (2C, Ar), 130.37 
(2C, Ar), 137.62 (1C, Ar), 165.52 (1C, C=O), 167.12 (1C, 
Ar), 178.37 (1C, C=S). IR (KBr), νmax (cm–1): 1663 
(C=O amide), 1663 and 1498 (C=C Aromatic), 3269 
and 1598 (NH strech sec. amides), 1108 and 805 (C=S). 
HRMS (m/z): C14H10N2OSF (M-H)– = 273.0507 and 
Calc. Mass = 273.0498. 
Table 3 presents the cytotoxic test results (IC50) of 
the two test compounds in MCF-7 cancer cells and 
Vero normal cells. IC50 values of two test compounds 
were better than reference compound of hydroxyurea. 
The IC50 value of the 4-Br-BPCT compound was better 
than that of the 4-F-BPCT compound. This finding was 
similar to the activity predictions performed using 
in silico (Table 3). The smaller value of RS (stable 
bonding of drugs and receptors) could result in the 
better cytotoxic activities. In addition, the 4-Br-BPCT 
compound also had a better lipophilic value (0.86) 
compared with the 4-F-BPCT (0.14)[13,14].
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Compounds
RS 
(kcal/mol)
IC50 MCF-7 cells 
(mM)
IC50 Vero cells 
(mM)
4-Br-BPCT –85.4741 0.27 108.06
4-F-BPCT –83.5488 0.31 25.28
HU –38.4495 9.76 22.59
Figure 3. MCF-7 cells before administration of a test compound 
(4-Br-BPCT): living cells condition (a) and black arrow shows: MCF-7 
cells after administration of a test compound (4-Br-BPCT) with a 
dose of 1000 μg/mL: the presence of dead cells after administration 
of a test compound (4-Br-BPCT) (b).G
(a) 
(b) 

Table 3. RS, IC50 MCF-7 and Vero cells values of  two test compounds 
and reference compound.G
Copyright © 2018 Journal of Chinese Pharmaceutical Sciences, School of Pharmaceutical Sciences, Peking University        http://www.jcps.ac.cn
ww
.jcp
s.ac
.cn
701

4. Conclusions
In this study, we synthesized two new compounds, 
namely N-(phenylcarbamothioyl)-4-bromobenzamide and 
N-(phenylcarbamothioyl)-4-fluorobenzamide. They had 
in vitro cytotoxic activities against human breast 
cancer cells (MCF-7), which were higher than those of 
hydroxyurea-based anticancer drugs. The in silico 
prediction results proved that the RS values of the two 
new compounds were lower than those of the lead 
compound and HU. The RS of 4-Br-BPCT compound 
was lower than of 4-F-BPCT compound. The IC50 
values of N-(phenylcarbamothioyl)-3-bromobenzamide 
and  N-(phenylcarbamothioyl)-4-fluorobenzamide were 
0.27 mM  and 0.31 mM, respectively, and both were 
more active than hydroxyurea (IC50 = 9.76 mM). The 
cytotoxic effect of 4-Br-BPCT was higher than that of 
4-F-BPCT, and it may be related to 4-Br lipophilic 
values, which were higher than 4-F. These two new 
compounds were more suitable for binding enzymes 
compared with hydroxyurea, as they had better 
inhibitory activities. Collectively, these two new 
compounds could be used as new targets because they 
had toxic effects on cancer cells but not Vero normal 
cells. Further studies are required to examine the 
molecular mechanisms on EGFR receptor of these two 
new compounds.
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